+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Binge Eating Disorder - Pipeline Review, H1 2020

  • ID: 5024750
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 62 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Chronos Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Omeros Corp
  • OXonium Therapeutics
  • Seropeutics LLC
  • Sosei Heptares
  • MORE
Binge Eating Disorder - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Chronos Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Omeros Corp
  • OXonium Therapeutics
  • Seropeutics LLC
  • Sosei Heptares
  • MORE
  • Introduction
  • Report Coverage
  • Binge Eating Disorder - Overview
  • Binge Eating Disorder - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Binge Eating Disorder - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Binge Eating Disorder - Companies Involved in Therapeutics Development
  • Amygdala Neurosciences Inc
  • Chronos Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Omeros Corp
  • OXonium Therapeutics
  • Seropeutics LLC
  • Sosei Heptares
  • Sunovion Pharmaceuticals Inc
  • Vivus Inc
  • Binge Eating Disorder - Drug Profiles
  • (phentermine hydrochloride + topiramate) ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANS-6637 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-010018 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTDP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dasotraline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OMS-527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-5256390 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SERx-480 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Binge Eating Disorder - Dormant Projects
  • Binge Eating Disorder - Discontinued Products
  • Binge Eating Disorder - Product Development Milestones
  • Featured News & Press Releases
  • Nov 20, 2019: New Clinical data demonstrate VIVUS’ Qsymia is effective at reducing Binge Eating in patients with Binge-Eating Disorder or Bulimia Nervosa
  • Jul 30, 2019: Sunovion announces acceptance by the U.S. FDA of the new drug application for Dasotraline for the treatment of adults with moderate-to-severe binge eating disorder
  • May 02, 2019: Sunovion to present data on dasotraline at the 2019 American Psychiatric Association Annual Meeting
  • Jul 25, 2018: Sunovion announces positive top-line results from pivotal study evaluating Dasotraline in adults with binge eating disorder
  • May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
  • May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting
  • Sep 14, 2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress
  • Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
  • May 23, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
  • May 16, 2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase
  • Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
  • Oct 06, 2016: Study Finds New Approach to Block Binge Eating
  • Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Binge Eating Disorder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, H1 2020
  • Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, H1 2020
  • Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Binge Eating Disorder - Pipeline by Omeros Corp, H1 2020
  • Binge Eating Disorder - Pipeline by OXonium Therapeutics, H1 2020
  • Binge Eating Disorder - Pipeline by Seropeutics LLC, H1 2020
  • Binge Eating Disorder - Pipeline by Sosei Heptares, H1 2020
  • Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc, H1 2020
  • Binge Eating Disorder - Pipeline by Vivus Inc, H1 2020
  • Binge Eating Disorder - Dormant Projects, H1 2020
  • Binge Eating Disorder - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Binge Eating Disorder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amygdala Neurosciences Inc
  • Chronos Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Omeros Corp
  • OXonium Therapeutics
  • Seropeutics LLC
  • Sosei Heptares
  • Sunovion Pharmaceuticals Inc
  • Vivus Inc
Note: Product cover images may vary from those shown
Adroll
adroll